Travoprost implants (slow- and fast-eluting iDose TR; Glaukos) demonstrated a favorable safety profile and are noninferior to topical timolol 0.5% twice daily in subjects with open-angle glaucoma or ocular hypertension.

In a poster presentation given during the 2023 annual meeting of the American Academy of Ophthalmology, Inder Paul Singh, MD, presented data on 380 slow-eluting implant subjects, 385 fast-eluting implant subjects, and 385 timolol subjects. For the slow-eluting implant, mean IOP reductions ranged from 6.6 mmHg to 8.4 mmHg; for fast-eluting implant, from 6.4 mmHg to 8.3 mm Hg; and for timolol, from 6.6 mmHg to 7.4 mmHg. The investigators found that 81% of implant subjects were free of topical IOP-lowering medication at 1 year.